New macrolide expands treatment options for bovine respiratory disease (BRD) in cattle.
The new antimicrobial tildipirosin is now available on veterinary microbroth dilution susceptibility plates, enabling veterinary microbiology laboratories to perform antimicrobial susceptibility testing on organisms that cause bovine respiratory disease (BRD) in beef and non-lactating dairy cattle.
The Thermo Scientific Sensititre System, recognized for including one of the largest and most up-to-date selections of antimicrobials for susceptibility testing, with more than 40 veterinary-specific antimicrobials, is now the first to offer tildipirosin on microbroth dilution susceptibility plates. Tildipirosin is available globally on Sensititre veterinary custom plates, and it will be featured on additional standard plates in the future. A variety of other species-specific, standard diagnostic formats are also available for applications related to avian and poultry, bovine and porcine, companion animals, equine and mastitis.
“With the availability of tildipirosin on the Sensititre System, veterinary laboratories now have access to a broader range of vet-specific antimicrobials for susceptibility testing of BRD isolates, where increasing resistance has been limiting treatment options for veterinarians,” said Mario Gualano, president, Thermo Fisher Scientific microbiology.
The Sensititre System utilizes true minimum inhibitory concentration (MIC) results, which are essential to identifying antimicrobial resistance, and this provides greater sensitivity for better resistance tracking. True MIC results are also the best measure of antibacterial effect, which can assist with therapeutic choices and promote overall better patient care.
Zuprevo (tildipirosin, Merck Animal Health) is indicated for the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni in beef and non-lactating dairy cattle, and for the control of respiratory disease in beef and non-lactating dairy cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. The drug is prohibited from certain extra-label uses in the United States and Canada, however it may be approved in other countries for the treatment and metaphylaxis of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica and Haemophilus parasuis sensitive to tildipirosin.